Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof

A method for treating or ameliorating in a mammal a disorder or disease selected from the group consisting of:

• colon cancer, colorectal cancer, leukemia, breast cancer, skin cancer, prostate cancer, lung cancer, liver cancer, bone or cartilage disease, and osteoarthritis, the method comprising administering to the mammal a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof:
• wherein:
• R1 is -heteroarylR3R4;
• R2 is selected from the group consisting of H, -heteroarylR5, -heterocyclylR6 and -arylR7;
• R3 is selected from the group consisting of H, -heterocyclylR8, —NHC(═O)R9, —NHSO2R10, —NR11R12 and —(C1-6 alkyl)NR11R12;
• wherein R2 and R3 are not both H;
• R4 is 1-3 substituents each selected from the group consisting of H, C1-9 alkyl, halide, —CF3, —CN, OR13 and amino;
• each R5 is independently 1-4 substituents each selected from the group consisting of H, C1-9 alkyl, halide, —CF3, —CN, OR13, —C(═O)R11, amino and —(C1-6 alkyl)NR11R12;
• each R6 is independently 1-5 substituents each selected from the group consisting of H, C1-9 alkyl, halide, —CF3, —CN, OR13 and amino;
• each R7 is independently 1-5 substituents each selected from the group consisting of H, C1-9 alkyl, halide, —CF3, —CN, OR13, amino, —(C1-6 alkyl)NHSO2R11, —NR12(C1-6 alkyl)NR11R12 and —(C1-6 alkyl)NR11R12;
• R8 is 1-5 substituents each selected from the group consisting of H, C1-9 alkyl, halide, —CF3, —CN, OR13 and amino;
• R9 is selected from the group consisting of C1-9 alkyl, -heteroarylR5, -heterocyclylR6, -arylR7 and —CH2carbocyclyl;
• R10 is selected from the group consisting of C1-9 alkyl, -heteroarylR5, -heterocyclylR6, -arylR7, and -carbocyclylR14;
• each R11 is independently selected from C1-6 alkyl;
• each R12 is independently selected from the group consisting of H and C1-6 alkyl;
• each R11 and R12 are optionally linked to form a five or six membered heterocyclyl ring;
• each R13 is independently selected from the group consisting of H and C1-6 alkyl;
• and
• R14 is 1-5 substituents each selected from the group consisting of H, C1-9 alkyl, halide, —CF3, —CN, OR13 and amino;
• with the proviso that the compound of Formula I is not a compound selected from the group consisting of: